QSAM Biosciences (OTCQB: QSAM) is developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam(R)), for the treatment of bone cancer and related diseases and conditions. The company today announced clearance, by the U.S. Food & Drug Administration (“FDA”), of its amended clinical trial protocol increasing the maximum age of participants to 75 years old from the prior age limitation of 65. This amendment significantly expands the population of potential participants in QSAM’s phase 1 study evaluating CycloSam in the treatment of bone cancer. “We thank the FDA for clearing our amended clinical trial protocol, which should allow us to accept a greater percentage of the participants screened for enrollment, and, as a result, move the study ahead more quickly and efficiently,” said Douglas Baum, CEO of QSAM. “Our mission at QSAM is making sure the broadest possible population fighting this deadly disease may one day be able to benefit from CycloSam.”
To view the full press release, visit https://ibn.fm/11DUJ
About QSAM Biosciences Inc.
QSAM Biosciences is developing next-generation nuclear medicines for the treatment of cancer and related diseases. QSAM’s initial technology, CycloSam(R) (Samarium-153 DOTMP), is a clinical-stage bone-targeting radiopharmaceutical developed by IsoTherapeutics Group LLC, pioneers in the nuclear medicine space who also developed the FDA-approved Quadramet(R) (Samarium-153 EDTMP) radiopharmaceutical product. The QSAM team has designed the CycloSam product with the goal of overcoming the limitations of the Quadramet(R) (Samarium-153 EDTMP) product’s FDA-approved indications. QSAM is led by an experienced executive team and board of directors that have completed numerous FDA approvals and multiple successful biotech exits. For more information, visit the company’s website at https://QSAMBio.com.
NOTE TO INVESTORS: The latest news and updates relating to QSAM are available in the company’s newsroom at http://ibn.fm/QSAM
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork
